The present invention is directed to the field of phage therapy for the treatment and control of bacterial infections, in particular diabetic foot infections. More specifically, the present invention is directed to novel cocktails of bacteriophage strains F44/10, F1 25/10, F770/05, F510/08, F1 245/05, and/or variants thereof; and methods of using same in the treatment and prevention of bacterial infections, including cutaneous ulcers associated with diabetic foot infections, caused by, e.g., Staphylococcus aureus, Pseudomonas aeruginosa, and/or Acinetobacter baumannii. The cocktails are used as pharmaceutical compositions either alone or in further combination with other therapies, e.g., antibiotics, growth factors, or other standard, as well as non-standard, therapies for diabetic foot infections.